The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study,European Journal of Heart Failure

当前位置： X-MOL 学术 › Eur. J. Heart Fail. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

The impact of comorbidities on selexipag treatment effect in patients with pulmonary arterial hypertension: insights from the GRIPHON study
European Journal of Heart Failure ( IF 16.9 ) Pub Date : 2021-11-21 , DOI: 10.1002/ejhf.2369
Stephan Rosenkranz ₁ , Richard Channick ₂ , Kelly M Chin ₃ , Bartosz Jenner ₄ , Sean Gaine ₅ , Nazzareno Galiè ₆ , Hossein-Ardeschir Ghofrani ₇ , Marius M Hoeper ₈ , Vallerie V McLaughlin ₉ , Camille Du Roure ₄ , Lewis J Rubin ₁₀ , Olivier Sitbon ₁₁ , Victor Tapson ₁₂ , Irene M Lang ₁₃

Affiliation

Heart Center, University Hospital Cologne, and Cologne Cardiovascular Research Center (CCRC), Cologne, Germany.
University of California Los Angeles, Los Angeles, CA, USA.
UT Southwestern Medical Center, Dallas, TX, USA.
Actelion Pharmaceuticals Ltd, Allschwil, Switzerland.
Mater Misericordiae University Hospital, Dublin, Ireland.
DIMES, University of Bologna and IRCCS, S. Orsola University Hospital, Bologna, Italy.
University of Giessen and Marburg Lung Center, Giessen, Germany, member of the German Center for Lung Research, and Department of Medicine, Imperial College London, London, UK.
Department of Respiratory Medicine, Hannover Medical School and German Center for Lung Research, Hannover, Germany.
University of Michigan, Ann Arbor, MI, USA.
Division of Pulmonary and Critical Care Medicine, University of California, San Diego, CA, USA.
Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France.
Cedars-Sinai Medical Center, Los Angeles, CA, USA.
Division of Cardiology, Medical University of Vienna, Vienna, Austria.

The number of pulmonary arterial hypertension (PAH) patients with comorbidities is increasing and there are limited data on response to PAH-targeted therapies in this population. These post hoc analyses explored the effect of selexipag in PAH patients with cardiovascular comorbidities in the GRIPHON study.

中文翻译：